837 related articles for article (PubMed ID: 33193339)
1. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.
Ringdén O; Gustafsson B; Sadeghi B
Front Immunol; 2020; 11():567210. PubMed ID: 33193339
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.
Ringdén O; Moll G; Gustafsson B; Sadeghi B
Front Immunol; 2022; 13():839844. PubMed ID: 35371003
[TBL] [Abstract][Full Text] [Related]
3. Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.
Ringdén O; Sadeghi B
Stem Cells; 2024 Apr; 42(4):291-300. PubMed ID: 38204331
[TBL] [Abstract][Full Text] [Related]
4. Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease.
Ringden O; Baygan A; Remberger M; Gustafsson B; Winiarski J; Khoein B; Moll G; Klingspor L; Westgren M; Sadeghi B
Stem Cells Transl Med; 2018 Apr; 7(4):325-331. PubMed ID: 29533533
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease.
Sadeghi B; Remberger M; Gustafsson B; Winiarski J; Moretti G; Khoein B; Klingspor L; Westgren M; Mattsson J; Ringdén O
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1965-1969. PubMed ID: 31173898
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.
Mielcarek M; Storb R; Georges GE; Golubev L; Nikitine A; Hwang B; Nash RA; Torok-Storb B
Biol Blood Marrow Transplant; 2011 Feb; 17(2):214-25. PubMed ID: 20816818
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
9. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
10. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
Front Immunol; 2022; 13():959658. PubMed ID: 36189324
[TBL] [Abstract][Full Text] [Related]
11. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.
Lucchini G; Introna M; Dander E; Rovelli A; Balduzzi A; Bonanomi S; Salvadè A; Capelli C; Belotti D; Gaipa G; Perseghin P; Vinci P; Lanino E; Chiusolo P; Orofino MG; Marktel S; Golay J; Rambaldi A; Biondi A; D'Amico G; Biagi E
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1293-301. PubMed ID: 20350611
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.
Sadeghi B; Ringdén O; Gustafsson B; Castegren M
Front Immunol; 2022; 13():963445. PubMed ID: 36426365
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.
Yin F; Battiwalla M; Ito S; Feng X; Chinian F; Melenhorst JJ; Koklanaris E; Sabatino M; Stroncek D; Samsel L; Klotz J; Hensel NF; Robey PG; Barrett AJ
Stem Cells; 2014 May; 32(5):1278-88. PubMed ID: 24452962
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for graft versus host disease with a focus on cell therapies.
Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
16. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
[TBL] [Abstract][Full Text] [Related]
17. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation.
Min CK; Kim BG; Park G; Cho B; Oh IH
Bone Marrow Transplant; 2007 May; 39(10):637-45. PubMed ID: 17369865
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.
Morata-Tarifa C; Macías-Sánchez MDM; Gutiérrez-Pizarraya A; Sanchez-Pernaute R
Stem Cell Res Ther; 2020 Feb; 11(1):64. PubMed ID: 32070420
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.
Kuçi Z; Bönig H; Kreyenberg H; Bunos M; Jauch A; Janssen JW; Škifić M; Michel K; Eising B; Lucchini G; Bakhtiar S; Greil J; Lang P; Basu O; von Luettichau I; Schulz A; Sykora KW; Jarisch A; Soerensen J; Salzmann-Manrique E; Seifried E; Klingebiel T; Bader P; Kuçi S
Haematologica; 2016 Aug; 101(8):985-94. PubMed ID: 27175026
[TBL] [Abstract][Full Text] [Related]
20. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
